Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs.
In his new role, Dr Laidlaw will be particularly responsible for overseeing the anticipated launch of the healthcare company’s product Rayaldee.
Dr Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, which include Genzyme, Keryx, Neurocine Biosciences and Serono.
He previously served as Relypsa’s executive director, medical affairs and Sanofi’s national director for medical science liasons, medical affairs.
Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the management team in OPKO’s renal division.
“A well-conceived and executed medical education strategy is critical to Rayaldee’s acceptance by US healthcare professionals.”